Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.20.

A number of research firms recently issued reports on IMUX. Leerink Partners reiterated an "outperform" rating and set a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. Piper Sandler reissued an "overweight" rating and set a $28.00 price objective on shares of Immunic in a research report on Tuesday, July 16th. Leerink Partnrs raised Immunic to a "strong-buy" rating in a research report on Monday, September 9th. EF Hutton Acquisition Co. I raised Immunic to a "strong-buy" rating in a research note on Monday, September 16th. Finally, StockNews.com raised Immunic from a "sell" rating to a "hold" rating in a research note on Tuesday, August 13th.

Immunic Stock Down 2.2 %

IMUX traded down $0.03 during trading on Tuesday, reaching $1.31. 1,276,613 shares of the stock traded hands, compared to its average volume of 597,927. The stock's 50-day moving average is $1.52 and its 200 day moving average is $1.36. Immunic has a 12 month low of $0.95 and a 12 month high of $2.11. The stock has a market capitalization of $118.00 million, a PE ratio of -0.85 and a beta of 1.84.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period last year, the firm posted ($0.54) EPS. As a group, equities research analysts anticipate that Immunic will post -0.93 EPS for the current year.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Immunic in the first quarter valued at about $25,000. Ikarian Capital LLC lifted its position in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock worth $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Immunic in the first quarter valued at approximately $9,266,000. Finally, BVF Inc. IL purchased a new stake in shares of Immunic during the first quarter valued at approximately $11,752,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.